RxDoctor Payments Data

Alexea Gaffney-Adams, MD

Internal Medicine · E. Setauket, NYNPI 1609047067

Payments from drug & device makers

$380,259in general payments, 2019–2025

Across 855 payments — averaging $444.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$240K
  • Viiv Healthcare Company$133K
  • AbbVie$1K
  • AstraZeneca$1K
  • Merck$1K
  • Melinta Therapeutics, LLC$417
  • plus $4K from 28 others

What the payments were for

  • Consulting fees$27,2607%
  • Speaking & faculty fees$265,49470%
  • Travel & lodging$67,03318%
  • Food & beverage$20,3675%
  • Education$1060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$380,259 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$135,270
Medicare patients
300
Services billed
1,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine13$52,008
DescovyEmtricitabine/Tenofov Alafenam23$47,610
OzempicSemaglutide29$40,897
EliquisApixaban24$31,591
TivicayDolutegravir Sodium12$24,307
FarxigaDapagliflozin Propanediol11$17,223
MounjaroTirzepatide11$11,424
ErtapenemErtapenem Sodium22$8,564
MyrbetriqMirabegron11$7,426
Pitavastatin Calcium25$4,358
SynthroidLevothyroxine Sodium56$3,592
Levothyroxine Sodium160$2,929
Atorvastatin Calcium165$2,125
Metoprolol Succinate104$1,945
Rosuvastatin Calcium82$1,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Tivicay$132,618$76,31525 claims
GileadDescovy$240,306$47,61023 claims
Novo NordiskOzempic$215$40,89729 claims
PfizerEliquis$361$31,59124 claims
AstraZenecaFarxiga$1,146$17,22311 claims
Lilly USA, LLCMounjaro$19$11,42411 claims
AbbVieSynthroid$1,174$3,59256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in E. Setauket

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →